Market Cap: $4.31B
II
Indivior Pharmaceuticals Inc
INDV
NASDAQ (NASDAQ Global Select)USD
Market Cap: $4.31B
Indivior Pharmaceuticals Posts Strong Q4 Earnings, Driven by Sublocade Sales Indivior Pharmaceuticals announces significant growth in its fourth-quarter performance, reporting a revenue of $150 millio…
Driving Progress in Addiction Treatment: Indivior's Fourth Quarter Highlights Growth and Commitment Indivior Pharmaceuticals reports a solid fourth-quarter performance that underscores its leadership…
Indivior's Milestone Inclusion in the S&P SmallCap 600: A Step Forward in the Fight Against Opioid Use Disorder Indivior PLC, a leading pharmaceutical company specializing in treatments for opioid use…
Indivior's S&P SmallCap 600 Inclusion Marks a Strategic Advancement in Opioid Treatment Indivior PLC achieves a significant milestone with its inclusion in the S&P SmallCap 600® index, announced on De…
Indivior's Strategic Leap: Inclusion in the S&P SmallCap 600 Indivior PLC takes a significant step forward with its recent inclusion in the S&P SmallCap 600® index, a development that underscores its…
Innovative Breakthrough in Opioid Use Disorder Treatment: Indivior’s SUBLOCADE® Demonstrates Efficacy Indivior PLC announces promising outcomes from a recent randomized, double-blind clinical trial re…
Indivior’s Clinical Trial Success: A Game Changer in Opioid Use Disorder Treatment Indivior PLC announces promising outcomes from a recent clinical trial of its medication SUBLOCADE® (extended-release…
Indivior Moves Forward After Resolving Legacy DOJ Matter Indivior PLC announces a pivotal moment in its corporate journey by settling its legacy matter with the U.S. Department of Justice (DOJ) throug…
Indivior Resolves Legacy Legal Matters, Strengthening Commitment to Opioid Treatment Indivior PLC (Nasdaq: INDV) recently announces a significant development in its legal landscape, having resolved a…
Indivior's Strategic Position in a Competitive Landscape Indivior Plc, a leader in addiction treatment solutions, finds itself operating in a complex and evolving healthcare environment marked by incr…
Indivior's Innovative Approach to Opioid Use Disorder Treatment Indivior PLC has recently made strides in the treatment of opioid use disorder (OUD) with the publication of significant findings from a…
Indivior's Strategic Shift: Redomiciliation to Enhance U.S. Presence Indivior PLC announces a pivotal transition in its corporate structure, intending to shift its domicile from the United Kingdom to…
Indivior Plc Enhances Commitment to Opioid Use Disorder Management Through Key Investor Engagements Indivior Plc, a leading global pharmaceutical company headquartered in Richmond, VA, reinforces its…
Indivior PLC: Focus on Recovery and Treatment Innovations Indivior PLC stands at a critical juncture in its mission to combat opioid dependence through innovative treatment solutions. The company spec…